We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+10.61%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.92B
AUM Growth
+$154M
Cap. Flow
+$62.7M
Cap. Flow %
3.27%
Top 10 Hldgs %
26.22%
Holding
151
New
15
Increased
40
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
JELD icon
JELD-WEN Holding
JELD
+$18.8M
2
LII icon
Lennox International
LII
+$14.6M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.18M
4
TTD icon
Trade Desk
TTD
+$8.01M
5
VRNS icon
Varonis Systems
VRNS
+$7.91M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$21.1M
2
CYBR
CyberArk
CYBR
+$14M
3
ABBV icon
AbbVie
ABBV
+$10.1M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$9.2M
5
XPO icon
XPO
XPO
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 36.8%
2 Consumer Discretionary 13.92%
3 Technology 13.08%
4 Industrials 10.12%
5 Utilities 4.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
76
Xencor
XNCR
$1.59B
$6.86M 0.36%
313,000
– –
ZGNX
77
DELISTED
Zogenix, Inc.
ZGNX
$6.73M 0.35%
+168,000
New +$6.45M
BMRN icon
78
BioMarin Pharmaceuticals
BMRN
$11.7B
$6.69M 0.35%
75,000
– –
BHVN
79
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.53M 0.34%
242,000
+188,760
+355% +$5.2M
IFRX icon
80
InflaRx
IFRX
$253M
$5.76M 0.3%
+275,000
New +$4.96M
PTGX icon
81
Protagonist Therapeutics
PTGX
$8.92B
$5.72M 0.3%
275,000
+150,000
+120% +$2.66M
EXAS
82
DELISTED
Exact Sciences
EXAS
$5.25M 0.27%
100,000
– –
SUPN icon
83
Supernus Pharmaceuticals
SUPN
$2.65B
$5.18M 0.27%
130,000
– –
ATHN
84
DELISTED
Athenahealth, Inc.
ATHN
$4.92M 0.26%
37,000
– –
LKFT
85
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$4.88M 0.25%
52,000
– –
MYOK
86
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$4.63M 0.24%
110,000
+37,000
+51% +$1.43M
PRTA icon
87
Prothena Corp
PRTA
$440M
$4.5M 0.23%
120,000
– –
DBVT
88
DBV Technologies
DBVT
$817M
$4.18M 0.22%
17,000
– –
RARE icon
89
Ultragenyx Pharmaceutical
RARE
$2.56B
$4.05M 0.21%
87,400
– –
RGEN icon
90
Repligen
RGEN
$7.03B
$3.99M 0.21%
110,000
– –
ACRS icon
91
Aclaris Therapeutics
ACRS
$743M
$3.45M 0.18%
140,000
– –
DERM
92
DELISTED
Dermira, Inc.
DERM
$3.45M 0.18%
124,000
– –
FRTX
93
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$3.11M 0.16%
+5,397
New +$3.56M
TCON
94
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$3.02M 0.16%
4,500
– –
TTPH
95
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.92M 0.15%
23,185
– –
IRWD icon
96
Ironwood Pharmaceuticals
IRWD
$614M
$2.88M 0.15%
229,248
– –
NTUS
97
DELISTED
Natus Medical Inc
NTUS
$2.87M 0.15%
75,000
– –
REGN icon
98
Regeneron Pharmaceuticals
REGN
$77.4B
$2.82M 0.15%
7,500
– –
MGNX icon
99
MacroGenics
MGNX
$240M
$2.79M 0.15%
147,000
– –
DLPH
100
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
$2.76M 0.14%
+52,666
New +$2.74M
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Eventide Asset Management held 151 positions worth $1.92B, up 8.7% from $1.76B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management deployed $62.7M of net new capital in Q4 2017, opening 15 new positions and adding to 40 existing holdings. Its largest new stake was JELD-WEN Holding: 506,500 shares worth $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 38% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was bluebird bio, an estimated $21.1M trimmed.

  • Eventide Asset Management's largest Q4 2017 buy was JELD-WEN Holding: 506,500 shares worth $19.9M.
  • Eventide Asset Management added most to AveXis, Inc. Common Stock in Q4 2017, an estimated $8.18M increase.
  • Eventide Asset Management's biggest Q4 2017 reduction was bluebird bio, cutting an estimated $21.1M.
  • Eventide Asset Management fully exited CyberArk in Q4 2017, selling an estimated $14M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $1.92B portfolio in Q4 2017.
  • Eventide Asset Management opened 15 new positions and closed 11 in Q4 2017.
  • Eventide Asset Management's portfolio value rose 8.7% quarter-over-quarter to $1.92B.

Based on Eventide Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.